3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
10
Phase 1
2
Phase 3
1
Status
Terminated
1
Sponsor Class
NETWORK
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Colorectal Neoplasms
16
Parkinson Disease 4, Autosomal Dominant Lewy Body
3
Neoplasm Metastasis
3
Gastrointestinal Stromal Tumors
2
Carcinoma, Hepatocellular
2
Carcinoma
2
Adenocarcinoma
2
Spinocerebellar Degenerations
1
HER2-positive Colorectal Cancer
1
HER2 IHC3+ Advanced Colorectal Cancer
1
Colorectal Cancer Liver Metastases
1
Colonic Neoplasms
1
Advanced Colorectal Cancer
1
Interventions
Fluorouracil
72
Leucovorin
71
Oxaliplatin
47
Irinotecan
31
Capecitabine
24
Bevacizumab
23
Folfox protocol
20
Cetuximab
15
Chemotherapy, Adjuvant
13
Celecoxib
7
Aspirin
6
Laparoscopy
5
XELOX
4
Panitumumab
4
Neoadjuvant Therapy
4
Levamisole
4
dehydroftorafur
3
Tegafur
3
Surgical Procedures, Operative
3
Observation
3
Floxuridine
3
vatalanib
2
tislelizumab
2
pertuzumab
2
encorafenib
2
atezolizumab
2
Trastuzumab
2
Standard of Care
2
Semaxinib
2
Selenium
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 3
×
Colonic Neoplasms
×
regorafenib
×
Clear all
NCT02664077
2022-04-14
ARGO
NSABP Foundation Inc
Phase 3
Terminated
34 enrolled